MethylGene Reports Favorable Phase I Data for MGCD265 in Solid Tumors at the AACR-NCI-EORTC International Conference
11/17/2009 11:17:39 AM
More...
|
MethylGene to Present at the 8th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/21/2009 2:35:32 PM
More...
|
MethylGene Issues Shares to Otsuka Pharmaceutical Co., Ltd.
10/21/2009 1:24:45 PM
More...
|
MethylGene Announces Equity Investment From Otsuka Pharmaceutical Co., Ltd.
10/15/2009 9:45:52 AM
More...
|
MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat)
9/21/2009 11:38:41 AM
More...
|
MethylGene Presents Phase I Data for its Novel Antifungal Agent, MGCD290, at the 49th Annual ICAAC Meeting
9/15/2009 11:04:16 AM
More...
|
MethylGene Presents Preclinical Data for Its Beta-Lactamase Inhibitor, MG96077, at the 49th Annual ICAAC Meeting
9/14/2009 11:26:20 AM
More...
|
MethylGene and Otsuka Pharmaceutical Co., Ltd. Extend Funded Research Collaboration; Methylgene Could get up to $50.5 Million
9/9/2009 6:53:08 AM
More...
|
MethylGene to Present Data at the 49th Annual ICAAC Meeting
9/8/2009 11:11:25 AM
More...
|
MethylGene Initiates Phase II Program for MGCD265 in Solid Tumors and Non-Small Cell Lung Cancer Patients
9/2/2009 11:41:19 AM
More...
|
|